Feature

Number of Medicare part D drug plans continues to decline


 

There will be 16% fewer Medicare part D prescription drug plans available in 2017, compared with 2016, according to an analysis by the Kaiser Family Foundation.

In 2017, there will be 746 stand-alone prescription drug plans available to Medicare beneficiaries in the 50 states and the District of Columbia, which is 140 (16%) less than were available in 2016 and 1,129 (60%) less than the peak in 2007, Kaiser reported.

Number of Medicare part D stand-alone prescription drug plans
The number of plans available without a premium to enrollees getting the low-income subsidy will go up to 231 in 2017 from 226 in 2016, but, again, there has been an overall decline since part D started in 2006, Kaiser said.

Of the nearly 41 million people enrolled in Medicare part D plans in 2016, about 12 million receive the low-income subsidy. The Congressional Budget Office estimates that spending on part D benefits will be $94 billion in 2017, which is 15.6% of overall Medicare costs. Medicare actuaries have projected that the cost per enrollee will increase by 5.8% annually from 2015 to 2025, Kaiser reported.

Recommended Reading

Uninsured rate lowest in Massachusetts
MDedge Hematology and Oncology
CMS offering educational webinars on MACRA
MDedge Hematology and Oncology
Access issues looming as more docs eye exit from clinical practice
MDedge Hematology and Oncology
Analysis: CMS expects no MACRA pay cut for most small practices
MDedge Hematology and Oncology
Medicare subsidies eliminate disparities in adherence to hormonal
MDedge Hematology and Oncology
Growth in hospital-employed physicians shows no signs of slowing
MDedge Hematology and Oncology
Doctors have at least seven APM options in 2017
MDedge Hematology and Oncology
Drug prices, not the health law, top voters’ health priorities for 2017
MDedge Hematology and Oncology
Texas medical board drops appeal against Teladoc
MDedge Hematology and Oncology
7 tips for successful value-based care contracts
MDedge Hematology and Oncology